design
synthesi
xray
crystal
structur
molecular
model
biolog
evalu
seri
new
gener
sarscov
plpro
inhibitor
describ
new
lead
compound
identifi
via
highthroughput
screen
divers
chemic
librari
subsequ
carri
lead
optim
structureact
studi
provid
seri
improv
inhibitor
show
potent
plpro
inhibit
antivir
activ
sarscov
infect
vero
cell
interestingli
inhibitor
enzym
ic
antivir
ec
correspond
r
ic
antivir
ec
potent
compound
seri
nearli
equival
enzymat
inhibit
antivir
activ
proteinligand
xray
structur
sarscov
plpro
correspond
model
dock
plpro
provid
intrigu
molecular
insight
ligandbind
site
interact
pdb
access
code
plpro
xray
structur
support
inform
avail
biochem
event
critic
viral
replic
reveal
number
import
target
therapeut
intervent
sar
notabl
two
cystein
proteas
papainlik
proteas
plpro
proteas
play
critic
role
virusmedi
rna
replic
surprisingli
numer
studi
relat
develop
sarscov
inhibitor
alreadi
report
contrast
inhibitor
design
effort
sarscov
plpro
report
recent
report
discoveri
design
seri
unpreced
noncoval
sarscov
plpro
inhibitor
display
antivir
activ
sarscov
associ
cytotox
subsequ
proteinligand
xray
structur
provid
import
molecular
insight
design
optim
inhibitor
initi
work
demonstr
plpro
viabl
target
develop
antisar
therapeut
besid
viral
peptid
cleavag
recent
structur
function
studi
demonstr
plpro
involv
number
import
biochem
event
deubiquitin
deisgyl
involv
viru
evas
innat
immun
respons
homolog
enzym
human
coronaviru
shown
critic
viral
replic
addit
recent
studi
shown
human
deubiquitin
enzym
potenti
anticanc
drugdesign
target
thu
plpro
signific
target
drug
develop
varieti
human
diseas
recent
primari
screen
librari
divers
druglik
compound
led
identif
two
compound
lead
valid
lead
reproduc
inhibit
plpro
dose
depend
manner
absenc
presenc
tritonx
subsequ
optim
effort
potent
lead
contain
benzamid
scaffold
ic
led
design
novel
plpro
inhibitor
relat
deriv
display
antivir
activ
sarscov
recent
report
detail
studi
describ
synthesi
biolog
studi
xray
structur
proteinligand
complex
plpro
continu
studi
toward
develop
noncovalentrevers
plpro
inhibitor
investig
potenti
second
less
potent
lead
evolv
highthroughput
screen
effort
second
ht
lead
compound
figur
contain
piperidin
carboxamid
scaffold
exhibit
ic
valu
subsequ
lead
optim
effort
led
design
potent
inhibitor
ic
inhibit
sarscov
viral
replic
vero
cell
ec
valu
correspond
enantiom
shown
slightli
less
potent
enzym
inhibitori
activ
ic
similar
antivir
potenc
proteinligand
xray
structur
sarscov
plpro
determin
interestingli
structur
reveal
uniqu
mode
bind
sarscov
plpro
key
molecular
interact
inhibitor
quit
differ
activesit
interact
inhibitor
herein
describ
design
synthesi
structureact
studi
molecular
model
proteinligand
xray
structur
biolog
evalu
seri
novel
noncoval
inhibitor
sarscov
plpro
ascertain
import
posit
methoxi
substitu
lead
inhibitor
synthes
correspond
deriv
shown
scheme
acid
coupl
use
n
hydrochlorid
edci
hydrat
hobt
presenc
nmethylmorpholin
nmm
ch
cl
provid
coupl
product
yield
respect
remov
bocgroup
exposur
trifluoroacet
acid
tfa
ch
cl
h
afford
respect
amin
reduct
amin
ghosh
et
al
sever
acut
respiratori
syndrom
sar
first
report
guangdong
provinc
china
novemb
sar
contagi
respiratori
ill
effect
treatment
date
sar
affect
three
contin
infect
individu
caus
nearli
death
fortun
spread
sarscov
contain
initi
outbreak
public
health
measur
turn
etiolog
agent
sar
novel
coronaviru
sarscov
known
new
case
sar
sinc
howev
recent
isol
strain
zoonot
origin
thought
reservoir
sarscov
rais
possibl
reemerg
sar
relat
ailment
consequ
design
develop
antivir
effect
sarscov
import
prioriti
futur
outbreak
amin
use
na
oac
bh
presenc
acet
acid
furnish
inhibitor
yield
respect
structureact
studi
optim
potenc
plan
synthes
deriv
acid
coupl
variou
substitut
benzylamin
deriv
synthesi
substitut
acid
shown
scheme
alkyl
dimethylmalon
commerci
avail
presenc
kotbu
dmso
afford
malon
deriv
describ
previous
deprotect
ketal
function
carri
treatment
aqueou
hcl
thf
reaction
quench
solid
nahco
result
crude
dialdehyd
use
directli
subsequ
condens
reaction
condens
dialdehyd
variou
optic
activ
r
amin
amin
amin
amin
amin
aqueou
thf
h
afford
dihydropyridin
yield
catalyt
hydrogen
dihydropyridin
ethylacet
provid
variou
piperidin
deriv
yield
synthesi
variou
test
inhibitor
shown
scheme
treatment
diester
nacn
dmf
reflux
h
provid
methyl
ester
yield
dihydropyridin
deriv
similarli
convert
methyl
ester
twostep
sequenc
saponif
aqueou
lioh
mixtur
thf
methanol
water
h
afford
correspond
carboxyl
acid
coupl
result
carboxyl
acid
benzylamin
deriv
util
edci
presenc
diisopropylethylamin
describ
furnish
variou
inhibitor
excel
yield
evalu
effect
correspond
piperazin
deriv
sought
synthes
racem
piperazin
deriv
synthesi
outlin
scheme
reduct
amin
bocpiperazin
use
sodium
cyanoborohydrid
mixtur
methanol
acet
acid
h
afford
yield
remov
bocgroup
treatment
trifluoroacet
acid
ch
cl
h
provid
amin
treatment
presenc
n
ch
cl
follow
addit
stir
result
mixtur
h
afford
piperazin
deriv
yield
second
ht
lead
consider
weaker
first
lead
inhibitor
benzamid
deriv
ethylamin
enhanc
activ
first
investig
effect
deriv
plpro
inhibitori
activ
shown
tabl
deriv
show
poor
inhibitori
activ
deriv
howev
display
slightli
better
activ
start
lead
previou
structureact
lead
establish
ethyl
amid
significantli
potent
correspond
deriv
xray
structur
bound
plpro
demonstr
r
form
hydrophob
interact
aromat
ring
side
chain
prefer
r
methyl
also
document
point
interior
enzym
base
upon
ligandbind
site
interact
elect
incorpor
r
methyl
group
shown
tabl
r
methyl
deriv
display
ic
valu
ascertain
import
posit
methoxi
group
synthes
omethoxi
mmethoxi
deriv
interestingli
mmethoxi
deriv
exhibit
improv
enzym
inhibitori
activ
ic
valu
correspond
pmethoxi
deriv
also
shown
similar
potenc
enhanc
howev
deriv
show
reduct
potenc
examin
effect
r
naphthylethyl
deriv
potenc
shown
mmethoxi
omethoxi
benzylamid
display
signific
reduct
potenc
compar
r
naphthylethyl
deriv
respect
interestingli
naphthylethyl
deriv
potent
r
deriv
next
examin
effect
piperazin
ring
place
piperidin
prepar
compound
howev
piperazin
deriv
show
activ
plpro
like
piperazin
deriv
show
activ
plpro
due
structur
constraint
impos
carbon
nitrogen
replac
ring
new
nitrogen
attach
amid
group
form
urea
moieti
urea
moieti
tend
planar
impos
flexibl
constraint
gold
dock
show
amid
rotat
degre
away
optim
hydrogenbond
orient
data
shown
activ
compound
describ
structureact
studi
establish
mmethoxi
pmethoxi
deriv
equal
potent
preliminari
model
studi
indic
either
methoxi
oxygen
meta
para
within
proxim
form
hydrogen
bond
carboxamid
side
chain
base
upon
possibl
interact
incorpor
benzodioxolan
ring
examin
effect
inhibitori
potenc
shown
tabl
dioxolan
deriv
exhibit
potenc
compar
correspond
mand
pderiv
correspond
deriv
also
show
compar
enzym
inhibitori
activ
examin
prefer
methyl
group
hydrogen
posit
synthes
evalu
correspond
unsubstitut
deriv
shown
compound
display
signific
reduct
potenc
indic
import
methyl
group
also
examin
correspond
gemdimethyl
deriv
interestingli
compound
inact
indic
methyl
group
accommod
plpro
activ
site
antivir
activ
select
plpro
inhibitor
determin
result
shown
tabl
compound
assay
abil
rescu
vero
cell
cultur
sarscov
infect
viabil
virusinfect
vero
cell
function
inhibitor
concentr
measur
rel
mockinfect
cell
use
luminesc
assay
protocol
allow
evalu
inhibitor
efficaci
cytotox
observ
data
present
tabl
origin
ht
lead
show
antivir
activ
howev
deriv
show
compar
antivir
activ
inhibitor
substitu
display
antivir
activ
r
methyl
deriv
show
slightli
better
enzym
activ
methyl
deriv
inhibitor
exhibit
antivir
potenc
ec
interestingli
dioxolan
deriv
show
antivir
activ
approxim
compar
correspond
methoxi
benzamid
deriv
report
previou
studi
obtain
molecular
insight
ligandbind
site
interact
xray
crystal
structur
bound
plpro
determin
interestingli
bind
mode
key
molecular
interact
inhibitor
quit
differ
predict
differ
activesit
interact
benzamidederiv
inhibitor
previous
report
shown
figur
inhibitor
bind
activ
via
seri
interact
includ
hydrogenbond
form
carboxamid
nh
inhibitor
backbon
carbonyl
wrap
around
betaturn
bound
plpro
crystal
structur
also
confirm
presenc
structur
water
molecul
conserv
apo
enzym
pdb
inhibitor
bound
plpro
pdb
id
one
conserv
water
molecul
sit
pocket
shown
figur
sphere
residu
prevent
inhibitor
naphthyl
ring
occupi
pocket
stereo
imag
bound
plpro
also
show
two
water
molecul
near
residu
may
prevent
benzodioxolan
ring
flip
toward
figur
superimpos
previous
develop
inhibitor
demonstr
bind
mode
differ
significantli
two
inhibitor
interestingli
turn
region
also
show
signific
flexibl
particularli
case
inhibitor
pdb
id
peptid
bond
flip
degre
enabl
hydrogen
bond
interact
backbon
nitrogen
carboxamid
oxygen
inhibitor
carboxyamid
nitrogen
make
hydrogen
bond
side
chain
carboxyl
carboxi
amid
nitrogen
inhibitor
yellow
form
hydrogen
bond
backbon
carbonyl
oxygen
protein
shown
grey
naphthyl
ring
inhibitor
align
similar
fashion
hydrophob
pocket
form
residu
overlap
posit
one
conserv
water
molecul
observ
inhibitor
plpro
oxygen
atom
shown
sphere
pink
crystal
structur
inhibitor
plpro
oxygen
atom
shown
sphere
red
crystal
structur
shown
overlap
sphere
understand
sar
analog
ht
hit
compound
use
comput
model
explor
interact
seri
inhibitor
plpro
activ
seri
compound
independ
stereoisomer
contrast
seri
compound
synthes
first
ht
hit
compound
gold
redock
inhibitor
plpro
crystal
structur
describ
produc
heavi
atom
rmsd
crystal
structur
conform
indic
dock
satisfactorili
reproduc
experiment
structur
inhibitor
dock
ligand
remov
plpro
crystal
structur
residu
flag
flexibl
intern
strain
score
compound
correl
well
enzymat
activ
conserv
overlap
water
molecul
observ
chain
b
bound
plpro
crystal
structur
includ
dock
studi
investig
structur
basi
potenc
insensit
r
versu
configur
show
dock
model
inhibitor
superimpos
crystal
structur
plpro
figur
model
observ
invers
piperidin
ring
r
bind
mode
allow
naphthyl
ring
isom
accommod
activ
site
similar
orient
flexibl
piperidin
ring
also
act
spacer
group
enabl
carboxamid
nh
hydrogen
bond
backbon
carbonyl
oxygen
similar
fashion
therebi
retain
potenc
enantiom
howev
gemdimethyl
substitut
decreas
freedom
around
carbon
atom
lock
compound
conform
one
methyl
group
exhibit
bump
collis
side
chain
one
methyl
group
shift
almost
toward
residu
compar
singl
methyl
substitut
r
seen
figur
import
note
side
chain
lock
posit
hydrogen
bond
backbon
nh
henc
gemdimethyl
substitut
favor
accommod
activ
site
order
fit
hydrophob
methyl
group
near
hydrophil
residu
aspart
acid
side
chain
would
move
therebi
break
structur
hydrogen
bond
hypothesi
valid
goldscor
score
function
dock
studi
compound
heavili
penal
due
unfavor
intern
energi
term
compar
sum
intern
torsion
strain
intern
van
der
waal
energi
term
ligand
dock
flexibl
residu
also
suggest
side
chain
may
adopt
conform
might
enabl
hydrogen
bond
interact
one
benzodioxolan
oxygen
within
howev
dock
conform
gener
show
loss
hydrogen
bond
interact
closest
benzodioxolan
oxygen
least
away
side
chain
shown
figur
highlight
potenti
bump
collis
one
methyl
group
demonstr
two
methyl
group
accommod
favor
posit
previou
studi
discuss
sar
analog
first
ht
hit
evolut
inhibitor
great
detail
distinct
contrast
present
work
seri
compound
extrem
sensit
enantiomer
form
compound
dock
studi
conclud
r
form
activ
wherea
inact
conform
push
carboxamid
group
inhibitor
away
backbon
nh
inhibit
hydrogen
bond
format
loop
residu
conclus
design
synthes
evalu
novel
seri
sarscov
plpro
inhibitor
initi
lead
structur
ic
discov
via
highthroughput
screen
librari
divers
compound
preliminari
structureact
studi
systemat
modif
guid
xray
crystal
structur
plpro
subsequ
molecular
model
result
potent
inhibitor
enzym
inhibitori
ic
valu
nm
antivir
ec
valu
sarscovinfect
vero
cell
interestingli
correspond
isom
slightli
less
potent
ic
nm
plpro
inhibitori
assay
equipot
antivir
assay
correspond
gemdimethyl
deriv
significantli
less
potent
proteinligand
xray
structur
plpro
determin
resolut
structur
provid
critic
molecular
insight
ligand
bind
site
interact
appear
key
activ
site
interact
quit
differ
earlier
seri
inhibitor
design
improv
revers
sarscov
plpro
inhibitor
current
underway
laboratori
chemistri
hnmr
cnmr
spectra
record
varian
oxford
bruker
avanc
spectromet
optic
rotat
record
perkinelm
polarimet
anhydr
solvent
obtain
follow
ch
cl
distil
cah
thf
distil
na
benzophenon
solvent
reagent
grade
column
chromatographi
perform
whatman
mesh
silica
gel
low
pressur
psi
tlc
carri
e
merck
silica
gel
plate
puriti
test
compound
determin
hrm
hplc
analysi
differ
solvent
system
test
compound
show
puriti
titl
compound
obtain
describ
compound
tbutoxycarbonyl
solut
tbutoxycarbonyl
carbonyl
piperidin
mg
mmol
ch
cl
ml
trifluoroacet
acid
ml
ad
result
mixtur
stir
h
reaction
mixtur
dilut
ch
cl
basifi
slow
addit
satur
nahco
solut
layer
separ
aqueou
layer
extract
sever
time
ethyl
acet
combin
organ
layer
dri
anhydr
na
solvent
remov
reduc
pressur
furnish
amin
crude
amin
dri
ch
cl
ml
mmol
na
oac
bh
mg
mmol
acoh
mmol
ad
success
result
mixtur
stir
h
titl
compound
obtain
describ
compound
yield
viscou
liquid
solut
boc
mg
mmol
drych
cl
ml
ad
trifluoroacet
acid
ml
allow
stir
h
reaction
concentr
reduc
pressur
residu
ad
toluen
concentr
reduc
pressur
give
crude
compound
solut
mg
mmol
drych
cl
ml
ad
dropwis
mmol
argon
atmospher
allow
stir
h
mixtur
ad
dropwis
solut
drych
cl
ml
allow
stir
h
reaction
concentr
reduc
pressur
residu
purifi
silica
gel
column
chromatographi
furnish
compound
mg
white
amorph
solid
r
f
ch
cl
meoh
h
nmr
mhz
comput
analys
util
sybyl
suit
tripo
inc
gold
dock
program
ccdc
follow
previous
describ
protocol
complex
inhibitor
purifi
plpro
form
prior
crystal
incub
mgml
plpro
mm
tri
ph
mm
dtt
mm
diffractionqu
crystal
grew
sit
drop
contain
mgml
plpro
mm
nh
mm
me
ph
peg
crystal
flashfrozen
liquid
nitrogen
transfer
dri
nitrogen
stream
k
xray
data
collect
data
set
complex
collect
southeast
region
collabor
access
team
sercat
beamlin
advanc
photon
sourc
argonn
nation
laboratori
data
process
scale
use
program
suit
crystal
belong
spacegroup
two
monom
asymmetr
unit
inhibitorcomplex
structur
solv
molecular
replac
use
sarscov
plpro
apoenzym
structur
pdb
entri
search
model
amor
program
suit
manual
model
build
perform
use
wincoot
iter
round
posit
bfactor
refin
map
build
perform
use
cn
structur
deposit
pdb
code
stereo
represent
bound
plpro
includ
conserv
water
adjac
bind
site
may
influenc
bind
configur
describ
text
